Efectividad farmacológica en el tratamiento agudo de la esquizofrenia. Revisión sistemática
Pharmacological effectiveness in the acute treatment of schizophrenia. A systematic review
Resumen
Abstract
Bibliografía
1.Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectrums. Cambridge University Press. 2016;21(4):349–54. https://doi.org/10.1017/S1092852916000316
2.Tan N, van Os J. The schizophrenia spectrum and other psychotic disorders in the DSM-5. Tijdschr Psychiatr. 2014;56(3):167-72. Dutch [internet]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24643825. [acceso 02/04/2020]
3.Zhang W, Lei D, Keedy SK, Ivleva EI, Eum S, Yao L, Tamminga CA, Clementz BA, Keshavan MS, Pearlson GD, Gershon ES, Bishop JR, Gong Q, Lui S, Sweeney JA. Brain gray matter network organization in psychotic disorders. Neuropsycho-pharmacology.2020;45(4):666-674. https://doi.org/10.1038/s41386-019-0586-2.
4.World Health Organization [internet].Trastornos mentales. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/mental-disorders, 2019. [acceso 02/04/2020]
5.Hany M, Rehman B, Azhar Y, et al. Schizophrenia. [internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK539864/ [acceso: 12/03/2020]
6.World Health Organization [internet]. Esquizofrenia. Disponible en: https://www.who.int/topics/schizophrenia/es/, 2020. [acceso: 02/04/2020]
7. Moreno B, Martín C, y Almenara J. Revisión crítica de las fuentes de variabilidad en la medición de la prevalencia de esquizofrenia. Salud Mental. 2014;37(2):127-138.
https://doi.org/10.17711/SM.0185-3325.2014.016.
8.Castro-de-Araujo LFS, Allin M, Picchioni MM, Mcdonald C, Pantelis C, Kanaan RAA. Schizophrenia moderates the rela-tionship between white matter integrity and cognition. Schizophr Res. 2018;199:250-256. https://doi.org/10.1016/j.schres.2018.03.033.
9. Bora E, Yücel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-5 criteria and beyond. Schizophr Bull. 2010;36(1):36-42. https://doi.org/10.1093/schbul/sbp094.
10. Tomasella E, Bechelli L, Ogando MB, Mininni C, Di Guilmi MN, De Fino F, Zanutto S, Elgoyhen AB, Marin-Burgin A, Gelman DM. Deletion of dopamine D2 receptors from parvalbumin interneurons in mouse causes schizophrenia-like phe-notypes. Proc Natl Acad Sci U S A. 2018;115(13):3476-3481. https://doi.org/10.1073/pnas.1719897115.
11. Åsa Blomström, Håkan Karlsson, Renee Gardner, Lena Jörgensen, Cecilia Magnusson, Christina Dalman, Associations Between Maternal Infection During Pregnancy, Childhood Infections, and the Risk of Subsequent Psychotic Disorder—A Swedish Cohort Study of Nearly 2 Million Individuals. Schizophrenia Bulletin.2016; 42 (I):125–133. https://doi.org/10.1093/schbul/sbv112.
12. Vaucher, J., Keating, B., Lasserre, A. et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2018; 23:1287–1292. https://doi.org/10.1038/mp.2016.252.
13. Archibald L, Brunette MF, Wallin DJ, Green AI. Alcohol Use Disorder and Schizophrenia or Schizoaffective Disor-der. Alcohol Res. 2019;40(1):arcr.v40.1.06. https://doi.org/10.35946/arcr.v40.1.06.
14. Molteni S, Filosi E, Mensi MM, Spada G, Zandrini C, Ferro F, Paoletti M, Pichiecchio A, Bonoldi I, Balottin U. Predic-tors of Outcomes in Adolescents With Clinical High Risk for Psychosis, Other Psychiatric Symptoms, and Psychosis: A Longitudinal Protocol Study. Front Psychiatry. 2019;10:787. https://doi.org/10.3389/fpsyt.2019.00787.
15. Fusar-Poli P, Davies C, Rutigliano G, Stahl D, Bonoldi I, McGuire P. Transdiagnostic Individualized Clinically Based Risk Calculator for the Detection of Individuals at Risk and the Prediction of Psychosis: Model Refinement Including Non-linear Effects of Age. Front Psychiatry. 2019;9;10:313. . https://doi.org/10.3389/fpsyt.2019.00313.
16. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. 2014;39(9):638-45. Dispo-nible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159061/. [acceso: 02/04/2020]
17. Opare-Addo MNA, Mensah J, Aboagye GO. A Case of Schizophrenia in a Young Male Adult with no History of Sub-stance Abuse: Impact of Clinical Pharmacists' Interventions on Patient Outcome. Case Rep Psychiatry. 2020; 15. https://doi.org/10.1155/2020/3419609.
18. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020 7;6(1):1. https://doi.org/10.1038/s41537-019-0090-z.
19. Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Adv Ther. 2018;35(10):1612-1625. https://doi.org/10.1007/s12325-018-0785-y.
20. Hsu HF, Kao CC, Lu T, Ying JC, Lee SY. Differences in the Effectiveness of Long-Acting Injection and Orally Adminis-tered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services. J Clin Med. 2019 ;8(6):823. https://doi.org/10.3390/jcm8060823.
21. Emsley R, Kilian S. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatr Dis Treat. 2018; 5(14):205-223. https://doi.org/10.2147/NDT.S139633.
22. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): Revised Publication Guidelines From a Detailed Consensus Process. J Contin Educ Nurs. 2015. 46(11): 501-507. http://doi.org/10.3928/00220124-20151020-02.
23. Sağlam Aykut D. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medi-cation Adherence, Side Effects, and Quality of Life. J Clin Psychopharmacol. 2019;39(1):57-62. http://doi.org/10.1097/ JCP.0000000000000993.
24. Lynn Starr H, Bermak J, Mao L, Rodriguez S, Alphs L. Comparison of long-acting and oral antipsychotic treatment ef-fects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory anal-ysis of the PRIDE study. Schizophr Res. 2018;194:39-46. http://doi.org/ 10.1016/j.schres.2017.05.005.
25. Detke HC, Weiden PJ, Llorca PM, Choukour M, Watson SB, Brunner E, Ascher-Svanum H. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia. J Clin Psychopharmacol. 2014;34(4):426-34. http://doi.org/ 10.1097/JCP.0000000000000140.
26. Malla A, Chue P, Jordan G, Stip E, Koczerginski D, Milliken H, Joseph A, Williams R, Adams B, Manchanda R, Oyewumi K, Roy MA. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses. 2016;9(4):198-208. http://doi.org/10.3371/CSRP.MACH.061213.
27. Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM; PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015;41(2):449-59. http://doi.org/ 10.1093/schbul/sbu067.
28. Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral anti-psychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2-3):220-230. http://doi.org/10.1016/j.schres.2016.07.018.
29.Subotnik KL, Casaus LR, Ventura J, et al. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia : A Randomized Clinical Trial. JAMA Psychia-try. 2015;72(8):822–829. http://doi.org/10.1001/jamapsychiatry.2015.0270.
30.Hervás G, Ruano C, Sanz_Alfayate G, Algora I, Celdrán MAMur MA.Análisis del manejo de antipsicóticos inyectables de larga duración en varios centros penitenciarios. Rev Esp Sanid Penit.2019;21:94-101.
31. Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitali-sation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizo-phrenia. J Med Econ. 2013;16(7):917-25. http://doi.org/ 10.3111/13696998.2013.804411.
32. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsy-chotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of Clinical Epidemiology. 2013; 66(8):37-41. https://doi.org/10.1016/j.jclinepi.2013.01.012.
33. Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does Half-Life Matter After Antipsychotic Discontinua-tion? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. J Clin Psychiatry. 2017;78(7). http;//doi.org/ 10.4088/JCP.16m11308.
34. Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. Int Clin Psychopharmacol. 2016;31(6):315-22. http://doi.org/10.1097/YIC.0000000000000141.
35. Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsy-chotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involve-ment. Early Interv Psychiatry. 2018;12(1):55-65. http://doi.org/10.1111/eip.12271.
36. Kwon JS, Kim SN, Han J, Lee SI, Chang JS, Choi JS, Lee HJ, Cho SJ, Jun TY, Lee SH, Han C, Lee KU, Lee KK, Lee E. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Int Clin Psychopharmacol. 2015;30(6):320-8. http://doi.org/ 10.1097/YIC.0000000000000093.
37. Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014;53(6):533-43. http://doi.org/10.1007/s40262-014-0132-7.
38. Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 2016;10(5):365-77.
39. Sağlam Aykut D. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Med-ication Adherence, Side Effects, and Quality of Life. J Clin Psychopharmacol. 2019;39(1):57-62. http://doi.org/10.1097/JCP.0000000000000993.
40. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry. 2016;77(3):1-24. http://doi.org/10.4088/JCP.15032su1.
41. Castillo EG, Stroup TS. Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Evidence-based Mental Health. 2015;18(2):36-39. http://doi.org/10.1136/eb-2015-102086.
42. Lynn Starr H, Bermak J, Mao L, Rodriguez S, Alphs L. Comparison of long-acting and oral antipsychotic treatment ef-fects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory anal-ysis of the PRIDE study. Schizophr Res. 2018;194:39-46. http://doi.org/10.1016/j.schres.2017.05.005.
43. Alphs L, Schooler N, Lauriello J. How study designs influence comparative effectiveness outcomes: The case of oral versus long-acting injectable antipsychotic treatments for schizophrenia. Schizophrenia Research. 2014;156(2-3):228-232. https://doi.org/10.1016/j.schres.2014.04.024.
44. Wykes T, Rose D, Williams P, David AS. Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication. BMC Psychiatry. 2013; 151:13-28. http://doi.org/10.1186/1471-244X-13-28.
45. Crespo-Facorro B, Bernardo M, Argimon JM, Arrojo M, Bravo-Ortiz MF, Cabrera-Cifuentes A, Carretero-Román J, Franco-Martín MA, García-Portilla P, Haro JM, Olivares JM, Penadés R, Del Pino-Montes J, Sanjuán J, Arango C. Effec-tiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. Rev Psiquiatr Salud Ment. 2017;10(1):4-20. http://doi.org/ 10.1016/j.rpsm.2016.09.001.
- Resumen visto - 2114 veces
- PDF descargado - 476 veces
